Last reviewed 2026-04-20 · How we verify

Pexa-Vec

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Fever
• Lymphocyte count decreased
• Abdominal pain
• Anemia
• Chills
• Hyponatremia
• Lipase increased
• Nausea
• Platelet count decreased
• Activated partial thromboplastin time prolonged
• Anorexia
• Back pain

Key clinical trials

• A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer (PHASE1, PHASE2)
• A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma (PHASE1, PHASE2)
• Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (PHASE1)
• Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma (PHASE1, PHASE2)
• A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) (PHASE1, PHASE2)
• A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) (PHASE1, PHASE2)
• A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer (PHASE2)
• Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.